Annual Retained Earnings
$27.26 B
+$3.95 B+16.96%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual retained earnings is currently $27.26 billion, with the most recent change of +$3.95 billion (+16.96%) on 31 December 2023. During the last 3 years, it has risen by +$16.37 billion (+150.26%). REGN annual retained earnings is now at all-time high.REGN Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
$30.76 B
+$1.34 B+4.56%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly retained earnings is currently $30.76 billion, with the most recent change of +$1.34 billion (+4.56%) on 30 September 2024. Over the past year, it has increased by +$4.65 billion (+17.83%). REGN quarterly retained earnings is now at all-time high.REGN Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN Retained Earnings Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +17.0% | +17.8% |
| 3 y3 years | +150.3% | +83.7% |
| 5 y5 years | +418.8% | +366.9% |
REGN Retained Earnings High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +150.3% | at high | +83.7% |
| 5 y | 5 years | at high | +418.8% | at high | +366.9% |
| alltime | all time | at high | +2251.0% | at high | +2526.8% |
Regeneron Pharmaceuticals Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $30.76 B(+4.6%) |
| June 2024 | - | $29.41 B(+5.1%) |
| Mar 2024 | - | $27.98 B(+2.6%) |
| Dec 2023 | $27.26 B(+17.0%) | $27.26 B(+4.4%) |
| Sept 2023 | - | $26.10 B(+4.0%) |
| June 2023 | - | $25.09 B(+4.0%) |
| Mar 2023 | - | $24.12 B(+3.5%) |
| Dec 2022 | $23.31 B(+22.9%) | $23.31 B(+5.4%) |
| Sept 2022 | - | $22.11 B(+6.3%) |
| June 2022 | - | $20.79 B(+4.3%) |
| Mar 2022 | - | $19.94 B(+5.1%) |
| Dec 2021 | $18.97 B(+74.1%) | $18.97 B(+13.3%) |
| Sept 2021 | - | $16.74 B(+10.8%) |
| June 2021 | - | $15.11 B(+25.8%) |
| Mar 2021 | - | $12.01 B(+10.2%) |
| Dec 2020 | $10.89 B(+47.6%) | $10.89 B(+11.8%) |
| Sept 2020 | - | $9.74 B(+9.5%) |
| June 2020 | - | $8.90 B(+11.2%) |
| Mar 2020 | - | $8.00 B(+8.5%) |
| Dec 2019 | $7.38 B(+40.5%) | $7.38 B(+12.0%) |
| Sept 2019 | - | $6.59 B(+11.3%) |
| June 2019 | - | $5.92 B(+3.4%) |
| Mar 2019 | - | $5.73 B(+9.0%) |
| Dec 2018 | $5.25 B(+78.3%) | $5.25 B(+18.5%) |
| Sept 2018 | - | $4.43 B(+15.5%) |
| June 2018 | - | $3.84 B(+16.8%) |
| Mar 2018 | - | $3.29 B(+11.6%) |
| Dec 2017 | $2.95 B(+68.6%) | $2.95 B(+6.3%) |
| Sept 2017 | - | $2.77 B(+16.3%) |
| June 2017 | - | $2.38 B(+19.4%) |
| Mar 2017 | - | $2.00 B(+14.2%) |
| Dec 2016 | $1.75 B(+105.0%) | $1.75 B(+16.9%) |
| Sept 2016 | - | $1.50 B(+21.5%) |
| June 2016 | - | $1.23 B(+20.8%) |
| Mar 2016 | - | $1.02 B(+19.4%) |
| Dec 2015 | $852.70 M(+293.6%) | $852.70 M(+22.2%) |
| Sept 2015 | - | $697.71 M(+43.2%) |
| June 2015 | - | $487.31 M(+66.5%) |
| Mar 2015 | - | $292.67 M(+35.1%) |
| Dec 2014 | $216.64 M(-333.7%) | $216.64 M(+49.2%) |
| Sept 2014 | - | $145.21 M(+121.7%) |
| June 2014 | - | $65.49 M(-340.3%) |
| Mar 2014 | - | -$27.25 M(-70.6%) |
| Dec 2013 | -$92.69 M(-82.1%) | -$92.69 M(-51.1%) |
| Sept 2013 | - | -$189.50 M(-42.7%) |
| June 2013 | - | -$330.80 M(-20.9%) |
| Mar 2013 | - | -$418.18 M(-19.1%) |
| Dec 2012 | -$517.05 M(-59.2%) | -$517.05 M(-47.6%) |
| Sept 2012 | - | -$987.46 M(-16.2%) |
| June 2012 | - | -$1.18 B(-6.1%) |
| Mar 2012 | - | -$1.26 B(-0.9%) |
| Dec 2011 | -$1.27 B(+21.2%) | -$1.27 B(+4.4%) |
| Sept 2011 | - | -$1.21 B(+5.4%) |
| June 2011 | - | -$1.15 B(+5.7%) |
| Mar 2011 | - | -$1.09 B(+4.2%) |
| Dec 2010 | -$1.05 B(+11.1%) | -$1.05 B(+1.4%) |
| Sept 2010 | - | -$1.03 B(+3.4%) |
| June 2010 | - | -$997.09 M(+2.6%) |
| Mar 2010 | - | -$971.62 M(+3.2%) |
| Dec 2009 | -$941.10 M(+7.8%) | -$941.10 M(+4.0%) |
| Sept 2009 | - | -$904.61 M(+0.1%) |
| June 2009 | - | -$903.59 M(+1.1%) |
| Mar 2009 | - | -$893.41 M(+2.3%) |
| Dec 2008 | -$873.26 M(+10.1%) | -$873.26 M(+3.4%) |
| Sept 2008 | - | -$844.41 M(+2.6%) |
| June 2008 | - | -$823.29 M(+2.3%) |
| Mar 2008 | - | -$804.84 M(+1.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | -$793.22 M(+15.4%) | -$793.22 M(+1.7%) |
| Sept 2007 | - | -$780.15 M(+4.8%) |
| June 2007 | - | -$744.31 M(+3.7%) |
| Mar 2007 | - | -$717.53 M(+4.4%) |
| Dec 2006 | -$687.62 M(+17.5%) | -$687.62 M(+4.7%) |
| Sept 2006 | - | -$656.65 M(+4.4%) |
| June 2006 | - | -$629.24 M(+3.9%) |
| Mar 2006 | - | -$605.66 M(+3.5%) |
| Dec 2005 | -$585.28 M(+19.5%) | -$585.28 M(+5.3%) |
| Sept 2005 | - | -$555.61 M(+6.7%) |
| June 2005 | - | -$520.96 M(+5.5%) |
| Mar 2005 | - | -$493.96 M(+0.8%) |
| Dec 2004 | -$489.83 M(-7.8%) | -$489.83 M(-0.6%) |
| Sept 2004 | - | -$492.63 M(+2.3%) |
| June 2004 | - | -$481.55 M(+3.1%) |
| Mar 2004 | - | -$467.00 M(-12.1%) |
| Dec 2003 | -$531.53 M(+25.3%) | -$531.53 M(+3.8%) |
| Sept 2003 | - | -$512.16 M(+6.1%) |
| June 2003 | - | -$482.92 M(+6.3%) |
| Mar 2003 | - | -$454.19 M(+7.1%) |
| Dec 2002 | -$424.07 M(+41.5%) | -$424.07 M(+9.2%) |
| Sept 2002 | - | -$388.38 M(+9.2%) |
| June 2002 | - | -$355.57 M(+9.4%) |
| Mar 2002 | - | -$325.14 M(+8.5%) |
| Dec 2001 | -$299.70 M(+34.1%) | -$299.70 M(+10.5%) |
| Sept 2001 | - | -$271.32 M(+7.9%) |
| June 2001 | - | -$251.39 M(+6.3%) |
| Mar 2001 | - | -$236.56 M(+5.8%) |
| Dec 2000 | -$223.52 M(+11.6%) | -$223.52 M(+4.6%) |
| Sept 2000 | - | -$213.78 M(+1.5%) |
| June 2000 | - | -$210.57 M(+1.4%) |
| Mar 2000 | - | -$207.62 M(+3.7%) |
| Dec 1999 | -$200.30 M(+13.0%) | -$200.30 M(+0.7%) |
| Sept 1999 | - | -$198.90 M(+2.5%) |
| June 1999 | - | -$194.00 M(+4.2%) |
| Mar 1999 | - | -$186.20 M(+5.1%) |
| Dec 1998 | -$177.20 M(+5.1%) | -$177.20 M(+3.2%) |
| Sept 1998 | - | -$171.70 M(+0.8%) |
| June 1998 | - | -$170.30 M(-1.2%) |
| Mar 1998 | - | -$172.40 M(+2.3%) |
| Dec 1997 | -$168.60 M(+7.4%) | -$168.60 M(-0.3%) |
| Sept 1997 | - | -$169.10 M(+1.1%) |
| June 1997 | - | -$167.20 M(+2.6%) |
| Mar 1997 | - | -$163.00 M(+3.8%) |
| Dec 1996 | -$157.00 M(+26.0%) | -$157.00 M(+5.4%) |
| Sept 1996 | - | -$148.90 M(+6.4%) |
| June 1996 | - | -$140.00 M(+5.7%) |
| Mar 1996 | - | -$132.40 M(+6.3%) |
| Dec 1995 | -$124.60 M(+23.2%) | -$124.60 M(+6.7%) |
| Sept 1995 | - | -$116.80 M(+6.6%) |
| June 1995 | - | -$109.60 M(+4.1%) |
| Mar 1995 | - | -$105.30 M(+4.2%) |
| Dec 1994 | -$101.10 M(+43.6%) | -$101.10 M(+6.0%) |
| Sept 1994 | - | -$95.40 M(+4.4%) |
| June 1994 | - | -$91.40 M(+12.6%) |
| Mar 1994 | - | -$81.20 M(+15.3%) |
| Dec 1993 | -$70.40 M(+130.1%) | -$70.40 M(+19.5%) |
| Sept 1993 | - | -$58.90 M(+19.5%) |
| June 1993 | - | -$49.30 M(+23.6%) |
| Mar 1993 | - | -$39.90 M(+30.4%) |
| Dec 1992 | -$30.60 M(+168.4%) | -$30.60 M(+26.4%) |
| Sept 1992 | - | -$24.20 M(+31.5%) |
| June 1992 | - | -$18.40 M(+25.2%) |
| Mar 1992 | - | -$14.70 M(+28.9%) |
| Dec 1991 | -$11.40 M(+62.9%) | -$11.40 M(+22.6%) |
| Sept 1991 | - | -$9.30 M(+9.4%) |
| June 1991 | - | -$8.50 M(+21.4%) |
| Dec 1990 | -$7.00 M | -$7.00 M |
FAQ
- What is Regeneron Pharmaceuticals annual retained earnings?
- What is the all time high annual retained earnings for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual retained earnings year-on-year change?
- What is Regeneron Pharmaceuticals quarterly retained earnings?
- What is the all time high quarterly retained earnings for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly retained earnings year-on-year change?
What is Regeneron Pharmaceuticals annual retained earnings?
The current annual retained earnings of REGN is $27.26 B
What is the all time high annual retained earnings for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual retained earnings is $27.26 B
What is Regeneron Pharmaceuticals annual retained earnings year-on-year change?
Over the past year, REGN annual retained earnings has changed by +$3.95 B (+16.96%)
What is Regeneron Pharmaceuticals quarterly retained earnings?
The current quarterly retained earnings of REGN is $30.76 B
What is the all time high quarterly retained earnings for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly retained earnings is $30.76 B
What is Regeneron Pharmaceuticals quarterly retained earnings year-on-year change?
Over the past year, REGN quarterly retained earnings has changed by +$4.65 B (+17.83%)